Skip to ContentSkip to Navigation
About usNews and EventsNews articles

Practice research in the field of gout: clinical pharmacology of antihyperuricemic drugs

28 November 2008

PhD ceremony: M.K. Reinders, 14.45 uur, Academiegebouw, Broerstraat 5, Groningen

Thesis: Practice research in the field of gout: clinical pharmacology of antihyperuricemic drugs

Promotor(s): prof. J.R.B.J. Brouwers, prof. M.A.F.J. van de Laar

Faculty: Mathematics and Natural Sciences

 

Gout is characterised by acute painful flares in the joints caused by deposition of monosodium urate crystals. The main factor is a high concentration of uric acid in the body. In literature, there are many reports of suboptimal treatment of gout. One of the reasons for this finding is a shortage of data on effective antihyperuricemic treatment strategies.

Mark Reinders investigated the clinical pharmacology of several antihyperuricemic agents (allopurinol, benzbromarone, probenecid, and rasburicase) in patients with gout with the focus on efficacy and tolerability in clinical practice.

One of his conclusions is that the most effective strategies are benzbromarone standard to high dosage (100-200 mg/day), allopurinol in high dosage (600 mg/day), and the combination allopurinol-probenecid combination. Allopurinol in standard dosage (300 mg/day) and probenecid are less effective, and probenecid is worse tolerated than benzbromarone.

Reinders also describes two cases of experimental treatment with rasburicase in two patients with refractory gout are. This novel, intravenous treatment has been proven highly effective in these patients.

Last modified:15 September 2017 3.37 p.m.
printView this page in: Nederlands

More news